NASDAQ:SYBX - Synlogic Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Synlogic Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.78 +0.03 (+1.09 %) (As of 02/21/2020 01:38 PM ET) Add Compare Today's Range$2.65Now: $2.78▼$2.8750-Day Range$2.35MA: $2.63▼$3.2052-Week Range$1.91Now: $2.78▼$10.04Volume17,783 shsAverage Volume443,618 shsMarket Capitalization$89.77 millionP/E RatioN/ADividend YieldN/ABeta2.59 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYBX Previous Symbol CUSIPN/A CIK1527599 Webhttp://www.synlogictx.com/ Phone617-401-9975Debt Debt-to-Equity Ratio0.14 Current Ratio12.70 Quick Ratio12.70Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.52 million Price / Sales35.62 Cash FlowN/A Price / Cash FlowN/A Book Value$4.88 per share Price / Book0.57Profitability EPS (Most Recent Fiscal Year)($2.03) Net Income$-48,440,000.00 Net Margins-4,574.82% Return on Equity-34.49% Return on Assets-28.75%Miscellaneous Employees74 Outstanding Shares32,290,000Market Cap$89.77 million Next Earnings Date3/10/2020 (Estimated) OptionableNot Optionable Receive SYBX News and Ratings via Email Sign-up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SYBX Rates by TradingView Synlogic (NASDAQ:SYBX) Frequently Asked Questions What is Synlogic's stock symbol? Synlogic trades on the NASDAQ under the ticker symbol "SYBX." When did Synlogic's stock split? How did Synlogic's stock split work? Synlogic shares reverse split before market open on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split. How were Synlogic's earnings last quarter? Synlogic Inc (NASDAQ:SYBX) issued its earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.48) by $0.09. The biotechnology company earned $0.31 million during the quarter, compared to the consensus estimate of $0.46 million. Synlogic had a negative net margin of 4,574.82% and a negative return on equity of 34.49%. View Synlogic's Earnings History. When is Synlogic's next earnings date? Synlogic is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Synlogic. What price target have analysts set for SYBX? 7 brokerages have issued 1 year price objectives for Synlogic's shares. Their forecasts range from $2.00 to $25.00. On average, they anticipate Synlogic's stock price to reach $14.17 in the next twelve months. This suggests a possible upside of 409.6% from the stock's current price. View Analyst Price Targets for Synlogic. What is the consensus analysts' recommendation for Synlogic? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synlogic. What are Wall Street analysts saying about Synlogic stock? Here are some recent quotes from research analysts about Synlogic stock: 1. According to Zacks Investment Research, "Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. " (1/9/2020) 2. HC Wainwright analysts commented, "We calculate an enterprise value of $480M, comprised of $280M for I/O portfolio. This yields a price objective of $13.00 per share, with approximately 37M fully-diluted shares outstanding as of mid-2020 (including exercise of approximately 2.5M outstanding options and all of the roughly 2.5M pre-funded warrants previously issued in the last private placement transaction)." (9/9/2019) Has Synlogic been receiving favorable news coverage? Headlines about SYBX stock have trended extremely negative recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Synlogic earned a coverage optimism score of -4.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Synlogic. Are investors shorting Synlogic? Synlogic saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,520,000 shares, an increase of 7.8% from the January 15th total of 1,410,000 shares. Based on an average daily volume of 474,400 shares, the days-to-cover ratio is presently 3.2 days. Approximately 8.6% of the company's shares are sold short. View Synlogic's Current Options Chain. Who are some of Synlogic's key competitors? Some companies that are related to Synlogic include MannKind (MNKD), Evofem Biosciences (EVFM), OptiNose (OPTN), AMAG Pharmaceuticals (AMAG), Syros Pharmaceuticals (SYRS), Lexicon Pharmaceuticals (LXRX), Osmotica Pharmaceuticals (OSMT), Syndax Pharmaceuticals (SNDX), Wave Life Sciences (WVE), Aduro BioTech (ADRO), Bicycle Therapeutics (BCYC), Kamada (KMDA), Gemphire Therapeutics (GEMP), Avadel Pharmaceuticals (AVDL) and VBI Vaccines (VBIV). What other stocks do shareholders of Synlogic own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Anavex Life Sciences (AVXL) and Progenics Pharmaceuticals (PGNX). Who are Synlogic's key executives? Synlogic's management team includes the folowing people: Dr. Peter Barrett, Exec. Chairman (Age 66)Dr. José Carlos Gutierrez-Ramos, Advisor (Age 56)Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Pres, CEO, Chief Medical Officer & Director (Age 43)Prof. Timothy K. Lu, Co-FounderDr. James J. Collins, Co-Founder Who are Synlogic's major shareholders? Synlogic's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.93%), State Street Corp (0.92%), Geode Capital Management LLC (0.78%), Bank of New York Mellon Corp (0.39%), Jacobs Levy Equity Management Inc. (0.31%) and Oxford Asset Management LLP (0.24%). Company insiders that own Synlogic stock include Paul Francis Miller and Richard P Shea. View Institutional Ownership Trends for Synlogic. Which major investors are selling Synlogic stock? SYBX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp. View Insider Buying and Selling for Synlogic. Which major investors are buying Synlogic stock? SYBX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Oxford Asset Management LLP, Bank of New York Mellon Corp, Geode Capital Management LLC, Virtu Financial LLC, Connor Clark & Lunn Investment Management Ltd. and Goldman Sachs Group Inc.. View Insider Buying and Selling for Synlogic. How do I buy shares of Synlogic? Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Synlogic's stock price today? One share of SYBX stock can currently be purchased for approximately $2.78. How big of a company is Synlogic? Synlogic has a market capitalization of $89.77 million and generates $2.52 million in revenue each year. The biotechnology company earns $-48,440,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. Synlogic employs 74 workers across the globe.View Additional Information About Synlogic. What is Synlogic's official website? The official website for Synlogic is http://www.synlogictx.com/. How can I contact Synlogic? Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected] MarketBeat Community Rating for Synlogic (NASDAQ SYBX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 276 (Vote Outperform)Underperform Votes: 234 (Vote Underperform)Total Votes: 510MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote "Outperform" if you believe SYBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2020 by MarketBeat.com StaffFeatured Article: What does cost of debt say about a company’s financial health?
